News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mallinckrodt Inc. and Zogenix, Inc. Announce Exclusive Co-Promotion Arrangement on SUMAVEL® DosePro®


6/7/2012 11:30:16 AM

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt LLC, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has entered into a co-promotion agreement with Zogenix Inc. (NASDAQ: ZGNX) for SUMAVEL®DosePro® (sumatriptan injection), a prescription medicine given with a needle-free delivery system to treat adults who have been diagnosed with acute migraine or cluster headaches.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES